Gene Solutions

Founded in 2017, Gene Solutions specializes in detecting the presence of certain diseases based on DNA markers of those diseases.

Their success was initially built on prenatal tests such as helping expecting parents to screen for disorders during their pregnancy or prevent genetic problems and assist with the conception of a child. They are currently the market leader for Non-Invasive Prenatal Testing (NIPT) in Vietnam.

In 2022, Gene Solution validated a liquid biopsy technology called SPOT-MASTM that can detect circulating tumor DNA (ctDNA) in the bloodstream as signals for multiple common types of cancers in the early stages, typically before they are easily detectable by traditional methods. The accessibility of a multi-cancer early detection test in the region has been well adopted by private hospitals and wellness centers in Ho Chi Minh City, Manila, Jakarta, and Bangkok. They also expect to open its oncology laboratory in Tai Seng Exchange, Singapore by November this year to fulfill growing cancer testing needs in the region.

The key to Gene Solution’s successful expansion is in its lower cost structure than its competitors, and its efforts to continuously lower the cost per test, making such tests more affordable for a wider range of end-users throughout Southeast Asia. Gene Solutions achieves this in part by running its own labs with a strong in-house research and development team.

Nearly 1,000,000 genetic tests have been provided by Gene Solutions, making genetic testing available to more people in South-East Asia countries where its services operated.

Gene Solutions raised $21 million in a Series B round backed by Mekong Capital in September 2023. In 2021, Mekong Capital invested $15 million in Gene Solutions.